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Abstract
Background: Despite of its global underuse, clozapine is still the golden standard antipsychotic for patients with treatment-resistant schizophrenia (TRS). 
Objective: To evaluate the patterns of clozapine and other antipsychotic drugs prescription in TRS in community mental health centers in São Paulo, Brazil. 
Methods: A multiple-choice questionnaire was applied to fifteen psychiatrists at five centers inquiring about patients’ clinical condition, adherence to oral 
treatment and current antipsychotic treatment. History of previous and current antipsychotic treatment was collected through medical chart review. Results: 
Out of 442 schizophrenia patients, 103 (23.3%) fulfilled the criteria for TRS. Fifty-eight patients (56.3%) were receiving polypharmacy; 30 (29.1%) were on 
atypical antipsychotic monotherapy, 14 (13.6%) were on typical antipsychotic monotherapy, 25 (24.3%) were taking depot antipsychotic medication and only 
22 (21.4%) were receiving clozapine. Discussion: As well as in other parts of the world, many TRS patients (78.6%) receive other drugs instead of clozapine in 
São Paulo, the best evidence-based medication for patients with TRS. The government should make every effort to provide medical training and the equipment 
and logistic support to adequately serve those who could benefit from clozapine treatment at the community health centers.
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Introduction
Antipsychotic drugs are the mainstay of the treatment of schizo-
phrenia, but although they are effective in the majority of patients, 
approximately 30% of this population has little or no benefit from 
conventional antipsychotic treatment1. These patients have more 
severe levels of psychopathology, greater number of episodes of 
illness and hospitalizations, and poorer quality of life compared 
to those who respond to treatment2,3. Their care also requires a 
disproportionately high proportion of the total cost of treating 
schizophrenia4. The term treatment-resistant schizophrenia (TRS) is 
currently applied to patients with persistance of moderate to severe 
levels of psychotic symptoms after at least two optimal treatments 
with different antipsychotic drugs5.
Brazil’s Constitution establishes health as a right for all and a duty 
of the State, thus in our country most of the patients with TRS are 
treated in public community mental health centers, named Centros 
de Atenção Psicossocial (CAPS), (Psychosocial Care Centers). These 
centers are located nationwide and assist people with the most severe 
mental disorders, providing intensive and multidisciplinary care, with 
focus on medical treatment and social reinsertion through access to 
labor, civil rights and leisure.
Clozapine, the first atypical antipsychotic agent, is the medi-
cation of choice when TRS is confirmed, and many studies have 
demonstrated its superiority over other antipsychotic compounds in 
such cases6-8. There are, however, drawbacks to the use of clozapine, 
foremost the need for regular blood counts, due to the increased 
risk for agranulocytosis, limiting the prescription of this medication. 
In fact, studies conducted worldwide have shown that clozapine 
prescription is less than the actual number of patients resistant to 
the antipsychotic treatment9. In Brazil, there is no study addressing 
neither the local population of TRS schizophrenic patients nor the 
pattern of antipsychotic prescription to these patients. 
A Brazilian federal law advocating for the rights and protection 
of people with mental disorders states that the mentally ill person 
must be granted to the best treatment available, according to his/her 
needs10. Since clozapine is the best treatment for TRS patients, the 
aim of the present study is to investigate wether clozapine is actually 
and adequately prescribed for patients with TRS as well as to evaluate 
the patterns of antipsychotic drugs prescription for patients with TRS 
in the CAPS of São Paulo. 
Methods
Study design 
A cross-sectional study was conducted in six CAPS of São Paulo.
Study population and assessment
By the time of the study, São Paulo Municipality counted with 20 
CAPS specialized in assisting adults with severe mental disorders 
and six of them entered the research. Although these CAPS’s catch-
ment area did not cover the whole city, the equipments appertained 
to the five different Regional Health Coordinations areas existing 
in São Paulo. This choice was made in order to involve the different 
realities of this megalopolis. The CAPS that entered the study were 
the first ones from which we had an acceptance in participate on it, 
which characterizes a convenience sample. We proceeded with the 
identification of all the patients with diagnoses ranging from F20 to 
F29 (schizophrenia, schizotypal and delusional disorders), according 
to the 10th Edition of the International Classification of Diseases 
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(ICD-10). All centers allowed us access to their files, which identified 
all attending patients with their respective diagnoses. 
Psychiatrists were invited to answer a multiple-choice question-
naire whereby they ranked, for each patient under their care, their 
current clinical condition, their adherence to antipsychotic treat-
ment and their current antipsychotic treatment, using the following 
instruments:
a. Current Clinical Condition was evaluated using the Clini-
cal Global Impression – Severity Scale (CGI-S). This scale 
assesses the clinician’s subjective impression of the current 
state of the patient’s illness. The rater is asked to “consider his 
total experience with the given population”. The time span 
considered is the week prior to the rating, and the following 
scores can be given: 1 = normal, not at all ill, 2 = borderline 
mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly 
ill, 6 = severely ill, and 7 = among the most extremely ill 
patients. We have chosen this scale because it is frequently 
used to evaluate the psychopathological state of patients with 
schizophrenia11, is easy to administer, is brief (it takes 1-2 min 
to be complete), has a good reliability in the clinical context 
and its results can be interpreted intuitively12.
b. Adherence to antipsychotic treatment was defined according 
to the following criteria: 1. Totally Adherent: patient takes 
virtually all the doses of the prescribed antipsychotic drugs; 2. 
Partially Satisfactory: patient takes the majority of the doses of 
the prescribed medication; 3. Partially Unsatisfactory: patient 
takes less than half of the doses of the prescribed antipsychotic 
drug; and 4. Completely Non-adherent: patient takes very few 
doses or no medication at all.
c. Information on current antipsychotic treatment was evalua-
ted according to psychiatrists’ answers to the questionnaire 
and classified into the following cathegories: 1. Typical An-
tipsychotic Drug Monotherapy; 2. Atypical Antipsychotic 
Drug Monotherapy; 3.  More than one Antipsychotic Drug; 
4. Clozapine Therapy (single or concomitant use with other 
drug); and 5. No Antipsychotic Drug Use. 
The questionnaire ended with an open question asking psy-
chiatrists which would be the most important obstacle to prescribe 
clozapine.
To find out which patients could be diagnosed with TRS, we first 
selected patients rated with a level of severity of at least moderately ill 
on CGI-S, i.e., CGI-S ≥ 4. They were considered poor responders and 
had their medical charts extensively reviewed. The CGI-S cut-off was 
the same used by Kane et al.13 to establish the cross-sectional criteria 
for TRS in a landmark study that demonstrated clozapine’s superior-
ity compared to chlorpromazine in TRS patients. The severity level 
defined as “moderately ill” in the CGI-S corresponds to approximately 
75 in the Positive and Negative Syndrome Scale (PANSS)14 which is a 
threshold degree of severity which is generaly accepted for inclusion 
criteria in studies that evaluate antipsychotic drug efficacy. 
All antipsychotic drugs previously and currently prescribed to 
the poor responder patients, including doses and length of treatment, 
were retrieved from the charts. Socio-demographic and clinical data 
such as number of previous hospitalizations and period of treatment 
in CAPS, amongst others, were also obtained. 
All patients considered poor responders who have had at least 
two adequate antipsychotic drug trials with different agents were 
defined as TRS patients, according to the recommendations of the 
Schizophrenia Algorithm of the International Pharmacological 
Algorithm Project5. An adequate trial was defined as a period of at 
least 8 weeks treatment with antipsychotic with doses at or above the 
drug therapeutic range15.
All patients taking clozapine also had their charts reviewed.
Inclusion and exclusion criteria for treatment-resistance
Inclusion criteria:
a) Patients diagnosed with schizophrenia or schizoaffective 
disorder (ICD-10: F20 or F25);
b) Poor responder patients that had, at least, two adequate 
antipsychotic drug trials with different agents or; 
c) Patients on clozapine therapy, independent of the CGI-S 
score.
Exclusion criteria:
a) Patients with a concomitant diagnosis of mental retardation 
(ICD-10: F70 to F79) or organic mental disorder (ICD-10: 
F06), in order to avoid misdiagnosis;
b) Partially unsatisfactory adherent and non-adherent patients 
and;
c) Patients whose last psychiatric evaluations were written more 
than 90 days prior, since changes in clinical status in this 
period could not be ruled out.
Statistical analysis
Descriptive statistics were used to describe the study sample, psy-
chiatrist’s responses and the chart findings. Statistical analysis was 
conducted using the SPSS 18.0 for Windows.
Ethical aspects
This study was approved by the research ethics committees of the 
Universidade Federal de São Paulo and the Municipal Health Office 
of São Paulo. 
We initiated the study after obtaining written consent from the 
directory board of each CAPS and from psychiatrists that agreed to 
participate in the research. 
Results
Six CAPS were invited to participate in the study with a total of 2,191 
patients: CAPS Pirituba-Jaraguá (n = 389); CAPS Itaim Paulista (n = 
976); CAPS Jardim Lídia (n = 45); CAPS Jabaquara (n = 188); CAPS 
Lapa (n = 192) and CAPS Perdizes (n = 401).
Psychiatrists from the CAPS Itaim Paulista were not able to coop-
erate with the study due to time constraints; therefore we have worked 
with a total of 1,215 patients (Figure 1). Fifteen out of 16 psychiatrists 
in the five remaining CAPS agreed to answer the questionnaire. A 
total of 442 (40.1%) patients had the diagnosis of schizophrenia or 
schizoaffective disorder without comorbidities like Mental Retarda-
tion and Organic Mental Disorder and were investigated in order to 
determine whether they fulfilled TRS inclusion criteria.
Thirty-six patients were excluded of the study because psychia-
trists had not completed the screening questionnaire regarding their 
clinical condition. A total of 171 patients (160 with scores ≥ 4 on 
CGI-S and 11 taking clozapine with scores < 4 on CGI-S) had their 
charts reviewed. Fifteen patients whose last psychiatric evaluations 
were performed more than 90 days were excluded.
The chart review showed that 53 of the patients not taking clo-
zapine did not fulfill the TRS criteria, due to the fact that 42 had not 
received adequate antipsychotic drug trials and 11 had an unsatisfac-
tory adherence to oral treatment.
Finally we found that 103 (23.3%) out of the 442 patients from 
the CAPS fulfilled the TRS inclusion criteria. 
The mean age of this group (n = 103) was 41.8 (SD: 12.78) years 
and 65 (63%) were men, with a mean duration of disease of 17.5 years 
(SD: 11.02). Schizophrenia was the diagnosis of the great majority 
(92.2%) of these patients. See table 1.
Figure 2 shows the antipsychotic drugs prescribed for the TRS 
group. The most frequently prescribed drugs were, in decreasing 
order, haloperidol (oral = 38, 36.9%; decanoate = 25, 24.3%), olan-
zapine (n = 32; 31.1%), chlorpromazine (n = 31; 30.1%) and clozapine 
(n = 22; 21.4%). Fifty-eight patients (56.3%) were taking more than 
one antipsychotic drug, 8 were taking 3 antipsychotic drugs and 1 
was taking 4 antipsychotic drugs; thirty (29.1%) were on atypical 
antipsychotic monotherapy and 14 (13.6%) were on typical antipsy-
chotic monotherapy. Six patients were taking clozapine in association 
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with another antipsychotic agent. In four cases the other drug was 
haloperidol, in the others, one was taking quetiapine and one was 
taking levomepromazine. 
Altogether, psychiatrists prescribed 100 typical and 81 atypical 
drugs. One patient (1.0%) was not taking any antipsychotic drug. 
The lifetime mean number of antipsychotic trials was 2.66 (SD: 1.69), 
but this number is probably underestimated, due to the difficulty of 
tracking antipsychotic prescriptions prior to the CAPS admission.
Nine psychiatrists (60%, n = 15) prescribed clozapine at least for 
one patient. Table 2 shows main obstacles associated to clozapine 
prescription according to psychiatrists. 
CAPS: Centro de Atenção Psicossocial; OMD: organic mental disorder; MR: mental 
retardation; CGI-S: Clinical Global Impression – Severity Scale; TR: treatment-
resistant.
Figure 1. Study population - from all patients to treatment-resistant patients.
Patients from all CAPS  
(n = 2,191)
Participant patients 
 (n = 1,001)
Schizophrenic and 
schizoaffective patients 
(n = 442)
Patients with
CGI-S ≥ 4 or on clozapine 
treatment
(n = 171) 
TR patients 
(n = 103)
CAPS Itaim Paulista lack of 
cooperation
(n = 976 excluded) 
Psychiatrist participation refusal
(n = 214 excluded)
Other diagnoses
(n = 599 excluded)
Comorbidity with OMD or MR
(n = 14 excluded)
Psychiatrist absence of answer
 (n = 36 excluded)
CGI-S < 4 and non-clozapine 
treatment
(n = 235 excluded)
Last registered psychiatric 
evaluation > 90 days 
(n = 15 excluded)
Antipsychotic drugs adequate 
trial < 2 
(n = 42 excluded) 
Non-adherent patients
(n = 11 excluded)
Table 1. Treatment-resistant schizophrenia patient’s characteristics (n = 103) 
Variable Treatment-resistant schizophrenia 
patients (n = 103)
Diagnosis – % (N) 92.2% (95) Schizophrenia, 7.8% (8) 
Schizoaffective Disorder
Gender – %(N) 36.9% (38) Female, 63.1% (65) Male
Age (Years) – Mean, (SD) 41.84 (12.78)
CGI-S – Mean (SD) 4.44 (1.10)
First Episode Age (Years) – Mean, (SD) 24.39 (10.32)
Disease Duration (Years) – Mean (SD) 17.58 (11.02)
First Treatment Age (Years) – Mean (SD) 26.97 (10.00)
Delay from First Episode and Treatment 
Initiation (Years) – Mean (SD)
2.14 (4.14)
Treatment Duration (Years) – Mean (SD) 15.04 (10.34)
Number of Antipsychotic Drugs 
adequately used through life – Mean (SD)
2.66 (1.70)
CAPS Treatment (Months) – Mean (SD) 92.18 (97.17)
Number of Hospitalizations – Mean (SD) 4.29 (6.06)
Number of Hospitalizations in the Past 
Year – Mean (SD)
0.18 (0.50)
SD: standard deviation; CGI-S: Clinical Global Impression – Severity Scale.
Figure 2. Antipsychotic drug treatment prescribed to treatment-resistant 
patients in CAPS.
36.9%
31.7% 30.10%
24.3% 21.4%
11.7% 10.7% 9.7%
Treatment-resistant patients 
Table 2. Obstacles to prescribe clozapine according to psychiatrists
Obstacles to prescribe clozapine % N
Patients low adherence to blood counts 53.33% 8
Laboratory delay in providing results and/or low reliability 26.67% 4
Psychiatrist lack of experience 13.33% 2
Dificulty in dosis titration 6.67% 1
Patients clinical comorbidities 6.67% 1
Lack of family support 6.67% 1
Discussion
In this study, which evaluated the antipsychotic drug prescription to 
103 patients who fulfilled criteria for TRS attending community cen-
ters in São Paulo, it was found that psychiatrists frequently prescribed 
antipsychotic polypharmacy for these patients and clozapine was 
offered for only a small percentage of them. Of these 103 individuals, 
fifty-eight (56.3%) were on a polypharmacy regimen of treatment. It 
is well known that combining antipsychotic drugs is a very common 
therapeutic practice16-18 in psychiatry, with some studies showing that 
the proportions of antipsychotic polypharmacy in United States of 
America and Canada are as high as 50%19,20. Nevertheless, its efficacy 
is not proven. The Clinical Antipsychotic Trials of Intervention Ef-
fectiveness (CATIE) study showed that antipsychotic combination 
was more prescribed to patients with high levels of symptoms, but 
in the end, it did not differ in terms of improving efficacy measures 
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compared to antipsychotic monotherapy21. Howes et al.22 and Alessi-
Severini et al.23 carried out studies at Mental Health Centers in Eng-
land and Canada, respectively, and found out that polypharmacy and 
three or more tries of antipsychotic treatment was a common feature 
before the initiation of clozapine. 
Regarding the patients with TRS, some meta-analyses support 
combining another antipsychotic with clozapine in patients who do 
not respond fully to this medication16,24,25 but the evidence of efficacy 
of these augmentation strategies is also scarce24.
As a group, atypicals were more prescribed in monotherapy 
(30%), but typicals were more prescribed in general (100 typical 
prescriptions against 81 atypical prescriptions at the time of the 
research), with haloperidol as the most prescribed agent, both in 
monotherapy and in polypharmacy. Social-economic conditions may 
play a role in the high prevalence of typical antipsychotic prescription. 
People who attend CAPS usually have low income, and the low cost of 
typical antipsychotic drugs makes them more affordable. Moreover, 
prescribing a typical antipsychotic drug requires minimal paperwork 
in comparison to atypical agents. In Brazil, the government subsi-
dizes treatment with several existing antipsychotic drugs, but while 
typical drugs can be obtained for free in public pharmacies, placed 
in numerous neighborhoods and thus easily accessible to everyone, 
in exchange of a regular prescription in duplicate, prescribing the 
atypical medications requires more paperwork because it is also 
necessary to fulfill a large protocol. These atypical antipsychotic drugs 
are listed in the Brazilian Program of High Cost Medications and are 
only available in Special Pharmacies, which exist in a number of two 
in São Paulo, a city of more than 11 million inhabitants. Therefore, 
even if the individual cost of the medications does not weigh in the 
choice of prescribing typical antipsychotics, the paperwork and the 
scantiness of Special Pharmacies probably contributes for the high 
prescription rates of haloperidol. 
The use of clozapine varies enormously according to different 
countries and settings, with higher prescription rates in China26 and 
Oceania27 and lower in North America28,29. The rates of clozapine pre-
scription for TRS patients found in Brazilian community centers were 
similar to rates found in studies carried out in the United States28,29, 
an especially low proportion when compared to other countries26,27,30. 
Clozapine was only prescribed for 22 individuals, which represents 
21.4% of the TRS patients, or 5% of the total number of schizophre-
nia patients, despite the abundant evidence of clozapine’s superior 
efficacy and effectiveness compared with other antipsychotic drugs 
in the treatment of TRS patients6,7,8,13,31,32. Current clinical practice 
guidelines for the treatment of schizophrenia recommend that a trial 
of clozapine should be offered after the identification of resistance to 
antipsychotic treatment1,15,33,34, which suggests that the major part of 
the psychiatrists participating in our study do not follow strictly to 
guideline recommendations, a feature also observed in other parts 
of the world22,35. 
Perhaps this scenario could be even worse in other parts of Bra-
zil, since unlike São Paulo, the country’s richest city, many cities do 
not have Special Pharmacies where people have access to high-cost 
medications. A generic clozapine formulation exists in Brazil for 
some years now, which allowed a cost reduction for consumers, but 
not enough to the very low-income stratum of our society. 
There are several obstacles to the use of clozapine that may 
impact negatively in its prescription rate, some of them related to 
the patients and their families, like refusal to take blood counts and 
fear of potential side effects, some of them related to its special treat-
ment regime, since clozapine requires slow dose titration and close 
monitoring during the initiation phase and careful management of 
treatment emergent side-effects. However, some studies underline 
that clinician-related factor are a main contribuitor to the low rates 
of clozapine prescription, as consultant psychiatrists may have little 
knowledge about certain aspects of clozapine, like its capacity to 
reduce suicide or drug abuse in patients with schizophrenia, and 
few experience in treating patients with this drug, since a significant 
number of the psychiatrists interviewed claimed to have had less than 
five patient on clozapine therapy36,37.
The majority of psychiatrists identified patients’ low adherence 
to blood routines as the main obstacle to prescribing clozapine. 
Psychiatrists tend to overestimate the patients’ annoyance with he-
matologic control36, which is in contrast with studies that focused 
on patient’s opinion and identified that blood tests are not an usual 
cause of concern among patients on clozapine38,39 and that they feel 
clinically better and prefer clozapine therapy over previously pre-
scribed antipsychotic drugs7,40,41. It is remarkable that only two of the 
participating CAPS can run the blood tests in their own facilities, 
while the other centers refer their patients to primary care units in 
order for them to obtain hematological exams. Psychiatrists beliefs 
also interfere since they may think that if the patients have to move 
to another care unit to get blood routines, this could affect their 
adherence to treatment.
Problems with the blood tests were also pointed as obstacles to 
prescribe clozapine. Psychiatrists reveal that there is a long delay 
from the taking of the blood sample until they receive their results. 
This delay, which may take one week, could represent the difference 
between a rapid identification of a mild neutropenia and its adequate 
management, or a missed neutropenia that progresses into a severe 
agranulocytosis.
This study has some limitations, mainly regarding the diagnostic 
of TRS. The number of drug trials was established retrospectively, 
relying on the information retrieved from medical records. We cannot 
assure that all of the changes in drug prescription were based on treat-
ment failure, since some medication changes might have had the goal 
of improving tolerability. However, the pattern of prescription among 
psychiatrists clearly shows an emphasis on polypharmacy, which, as 
discussed above, increase concerns about the risk of medication side 
effects. We believe, therefore, that the psychiatrists participating in 
our study are not primarily driven by tolerability concerns when 
prescribing antipsychotic drugs.
In addition to the number of adequate antipsychotic trials, we 
used the CGI-S to establish the diagnosis of TRS. This scale provides 
a global judgment of a patient’s overall state and it cannot determine 
what psychopathological aspect, in terms of positive or negative 
symptoms, the study clinicians were considering while rating their 
patients and how that influenced their decision on which drug to 
prescribe. For example, negative symptoms are prevalent throughout 
the disease42 and less responsive to antipsychotic treatment43, thus 
psychiatrists may consider that there is little advantage in changing 
antipsychotic drug regimen on the basis of negative symptoms. 
However, if the use of CGI-S lacks in psychopathological specificity, 
it allowed us to obtain psychiatrists’ opinion about the clinical status 
of their own patients in routine clinical practice, in a not burdensome 
or time-consuming manner.
Adherence to treatment was presumed by addressing psychia-
trists about their perception. Byerly et al.44 demonstrated a drastically 
underestimated antipsychotic non-adherence by clinicians when 
comparing antipsychotic adherence rates of outpatients assessed by 
electronic monitoring and by clinician rating. Therefore, we may also 
have underestimated non-adherence, leading to some inadequate 
TRS results.
This study endorses the low-adherence to treatment guidelines 
also found in other parts of the world. Its results can be potentially 
helpful in alerting psychiatrists and authorities of the low use of 
evidence-based treatments in São Paulo, which is demonstrated by 
the high prevalence of antipsychotic polypharmacy and the enormous 
gap between the prevalence of TRS in patients ordinarily treated in 
CAPS and clozapine prescription. Government authorities, legally 
committed to provide the most appropriate treatment to mentally 
ill people, should make every effort to supply the CAPS with the 
necessary equipment and logistic assistance to adequately serve pa-
tients who could benefit from Clozapine treatment. They also need 
to provide organizational and educational support in order to allow 
clinicians and staff to have the proper expertise for the identification 
of TRS and for the optimum management of clozapine, including the 
safest and most efficient monitoring of hematologic status.
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